Page last updated: 2024-11-12
6-deoxy-6-fluoronaltrexone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
6-deoxy-6-fluoronaltrexone: RN given refers to (5alpha,6beta)-isomer; RN for cpd without isomeric designation not available 2/91; opiate antagonist suitable for positron emission tomography [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10450257 |
| CHEMBL ID | 610282 |
| SCHEMBL ID | 2047900 |
| MeSH ID | M0183166 |
Synonyms (18)
| Synonym |
|---|
| cyclofoxy |
| CHEMBL610282 |
| 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-fluoromorphinan |
| 103223-57-0 |
| 6-deoxo-6beta-fluoronaltrexone |
| unii-669i3fr8vf |
| morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-fluoro-, (5alpha,6beta)- |
| (-)-cyclofoxy |
| 6-desoxy-6-fluoronaltrexone |
| 669i3fr8vf , |
| 6-deoxy-6-fluoronaltrexone |
| 6-deoxo-6.beta.-fluoronaltrexone |
| morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-fluoro-, (5.alpha.,6.beta.)- |
| 17-(cyclopropylmethyl)-3,14-dihydroxy-4,5.alpha.-epoxy-6.beta.-fluoromorphinan |
| SCHEMBL2047900 |
| DTXSID40145702 |
| Q27263985 |
| (4r,4as,7r,7ar,12bs)-3-(cyclopropylmethyl)-7-fluoro-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Opiate receptor avidity (B(max)'/K(D)) was measured in four rhesus monkeys following unilateral lesioning of the optic tract combined with transection of the corpus callosum and the hippocampal and anterior commissures depriving one hemisphere of visual input (Tract and Split), two animals with transection of commissures only (Split), and nine healthy monkeys with positron emission tomography (PET) and 6-deoxy-6-beta-[(18)F]fluoronaltrexone (cyclofoxy, CF), a mu- and kappa-opiate receptor antagonist." | ( Opiate receptor avidity is increased in rhesus monkeys following unilateral optic tract lesion combined with transections of corpus callosum and hippocampal and anterior commissures. Carson, RE; Cohen, RM; Doudet, DJ; Saunders, RC, 2000) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | IC50 (µMol) | 0.0079 | 0.0001 | 0.7298 | 10.0000 | AID148748 |
| Kappa-type opioid receptor | Mus musculus (house mouse) | IC50 (µMol) | 0.0079 | 0.0013 | 1.5380 | 10.0000 | AID148748 |
| Mu-type opioid receptor | Homo sapiens (human) | IC50 (µMol) | 0.0079 | 0.0001 | 0.8133 | 10.0000 | AID148748 |
| Delta-type opioid receptor | Homo sapiens (human) | IC50 (µMol) | 0.0079 | 0.0002 | 0.7521 | 8.0140 | AID148748 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 0.0369 | 0.0003 | 0.7123 | 7.0700 | AID148748; AID148849 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0103 | 0.0000 | 0.2018 | 6.4240 | AID149420; AID149968 |
| Kappa-type opioid receptor | Homo sapiens (human) | IC50 (µMol) | 0.0079 | 0.0000 | 1.2011 | 10.0000 | AID148748 |
| Mu-type opioid receptor | Mus musculus (house mouse) | IC50 (µMol) | 0.0079 | 0.0008 | 1.6992 | 10.0000 | AID148748 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (52)
Molecular Functions (12)
Ceullar Components (23)
Bioassays (12)
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (76.92) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.81
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.81) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||